1. Home
  2. IRD vs DHAI Comparison

IRD vs DHAI Comparison

Compare IRD & DHAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRD
  • DHAI
  • Stock Information
  • Founded
  • IRD 2018
  • DHAI 2007
  • Country
  • IRD United States
  • DHAI United States
  • Employees
  • IRD N/A
  • DHAI N/A
  • Industry
  • IRD
  • DHAI
  • Sector
  • IRD
  • DHAI
  • Exchange
  • IRD NYSE
  • DHAI NYSE
  • Market Cap
  • IRD 60.9M
  • DHAI 49.1M
  • IPO Year
  • IRD N/A
  • DHAI N/A
  • Fundamental
  • Price
  • IRD $1.12
  • DHAI $0.23
  • Analyst Decision
  • IRD Strong Buy
  • DHAI
  • Analyst Count
  • IRD 2
  • DHAI 0
  • Target Price
  • IRD $7.00
  • DHAI N/A
  • AVG Volume (30 Days)
  • IRD 2.1M
  • DHAI 662.8K
  • Earning Date
  • IRD 05-15-2025
  • DHAI 07-14-2025
  • Dividend Yield
  • IRD N/A
  • DHAI N/A
  • EPS Growth
  • IRD N/A
  • DHAI N/A
  • EPS
  • IRD N/A
  • DHAI N/A
  • Revenue
  • IRD $13,651,000.00
  • DHAI $69,573,000.00
  • Revenue This Year
  • IRD $22.00
  • DHAI N/A
  • Revenue Next Year
  • IRD $100.89
  • DHAI N/A
  • P/E Ratio
  • IRD N/A
  • DHAI N/A
  • Revenue Growth
  • IRD N/A
  • DHAI 5.40
  • 52 Week Low
  • IRD $0.65
  • DHAI $0.12
  • 52 Week High
  • IRD $2.18
  • DHAI $3.67
  • Technical
  • Relative Strength Index (RSI)
  • IRD N/A
  • DHAI 52.62
  • Support Level
  • IRD N/A
  • DHAI $0.21
  • Resistance Level
  • IRD N/A
  • DHAI $0.28
  • Average True Range (ATR)
  • IRD 0.00
  • DHAI 0.03
  • MACD
  • IRD 0.00
  • DHAI 0.00
  • Stochastic Oscillator
  • IRD 0.00
  • DHAI 57.14

About IRD OPUS GENETICS INC

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

About DHAI DIH HOLDINGS US INC

DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.

Share on Social Networks: